Ivermectin is generally not given to children weighing under 15 kg (33 lb) or under about five years of age. That limit is widely quoted and frequently misunderstood: it reflects an absence of trial data rather than a demonstration of harm. Above that threshold, ivermectin has been given to very large numbers of children with a well-characterised safety record.
The registration trials for ivermectin enrolled adults and older children. Younger children were not included, which is the norm in drug development, so the label reflects the population actually studied.
The specific theoretical concern is the blood-brain barrier. Ivermectin is kept out of the central nervous system by P-glycoprotein, an efflux transporter. There has been longstanding caution that this protective system may be less mature in very young children, which could in principle allow more drug into the brain.
Evidence for that concern actually materialising is thin. A World Health Organization review of the available data on ivermectin in children under 15 kg found no clear signal of increased harm, and concluded that the existing restriction was based more on absent data than on demonstrated risk. Several research groups have argued the threshold should be revisited.
Above 15 kg, children are dosed on exactly the same per-kilogram basis as adults. The 3mg tablet is the practical strength because it allows accurate dosing without splitting.
| Child weight | Weight (lb) | Dose at 200 mcg/kg | 3mg tablets |
|---|---|---|---|
| 15–24 kg | 33–53 lb | 3 mg | 1 |
| 25–35 kg | 55–77 lb | 6 mg | 2 |
| 36–50 kg | 79–110 lb | 9 mg | 3 |
| 51–65 kg | 112–143 lb | 12 mg | 4 |
Weigh the child rather than estimating. Paediatric dosing errors most often come from an assumed weight rather than a measured one.
Scabies is the most common. Children are heavily represented in scabies cases, and outbreaks in schools and households are difficult to control with topical treatment alone. Two oral doses 7 to 14 days apart is the standard schedule.
Head lice, where topical treatment has failed or resistance is suspected. Both oral ivermectin and a topical 0.5% lotion are used.
Intestinal worms, particularly strongyloidiasis, and in mass drug administration programmes for onchocerciasis and lymphatic filariasis where school-age children are a primary target group.
Mass drug administration programmes have given ivermectin to tens of millions of children in endemic regions over several decades. Adverse effects in that enormous population have been predominantly mild and transient: headache, dizziness, nausea and a temporary increase in itching as parasites die.
This is one of the larger real-world safety datasets that exists for any medicine in children, and it is the main reason clinicians are comfortable with ivermectin above the weight threshold.
The usual cautions still apply: it is a prescription medicine, dosing must be weight-based, and a child with a heavy parasite burden may have a more pronounced reaction to treatment. Any use in a child should be a clinician decision.
GMP-certified human formulations — tablets and 1% cream. Never veterinary products. Most USA orders ship within 1–7 business days, with tracking on every order.
View products and pricingYes, above 15 kg (33 lb) and roughly five years of age, using the same weight-based dosing as adults. Below that threshold it is generally avoided, and any use in a child should be directed by a clinician.
Because young children were not enrolled in the registration trials, so the label reflects the population studied. The theoretical concern is a less mature blood-brain barrier. A WHO review found no clear evidence of increased harm below 15 kg and concluded the limit rests on absent data rather than demonstrated risk.
The same 200 mcg/kg as adults for most indications. A 20 kg child needs 4 mg, a 30 kg child 6 mg, a 40 kg child 8 mg. Use 3mg tablets for accuracy and weigh the child rather than estimating.
It is widely used for exactly this, particularly for household and institutional outbreaks where topical treatment is impractical. Two doses 7 to 14 days apart is standard, because the drug does not kill mite eggs.
Most commonly headache, dizziness, nausea and a temporary worsening of itching as parasites die. These are usually mild and short-lived. Seek medical advice for severe or persistent symptoms, any rash, or any change in alertness or balance.